Literature DB >> 8215983

Gene therapy for neurologic disease.

S T Suhr1, F H Gage.   

Abstract

Gene therapy is a potentially potent new method of treating a number of neurologic disorders previously considered refractory to current conventional therapeutic treatments. Numerous advances have been made in the construction of expression vectors, cellular and viral transgene carriers, and the characterization of target cells for neuronal gene therapy. Two primary approaches to nervous system gene transfer have emerged as a result of these advances. The in vivo approach concentrates on direct transfer of genetic material to cells in vivo using viral and chemical agents. The ex vivo approach relies on genetic transfer to cultured cells that are subsequently implanted into a host organism. Both of these methods have been used in preliminary experiments designed to test the efficacy of gene transfer strategies in the amelioration of nervous system dysfunction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8215983     DOI: 10.1001/archneur.1993.00540110122012

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  7 in total

1.  Noninvasive gene targeting to the brain.

Authors:  N Shi; W M Pardridge
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

2.  Neuropathology of mice with targeted disruption of Hexa gene, a model of Tay-Sachs disease.

Authors:  M Taniike; S Yamanaka; R L Proia; C Langaman; T Bone-Turrentine; K Suzuki
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

Review 3.  Recent gene therapy advancements for neurological diseases.

Authors:  Sahana Nagabhushan Kalburgi; Nadia N Khan; Steven J Gray
Journal:  Discov Med       Date:  2013-02       Impact factor: 2.970

Review 4.  Neurogenetic diseases: molecular diagnosis and therapeutic approaches.

Authors:  U Muller; M B Graeber
Journal:  J Mol Med (Berl)       Date:  1996-02       Impact factor: 4.599

5.  Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease.

Authors:  S Yamanaka; M D Johnson; A Grinberg; H Westphal; J N Crawley; M Taniike; K Suzuki; R L Proia
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

Review 6.  Cell-based therapies for Parkinson's disease: past, present, and future.

Authors:  Kathleen M Fitzpatrick; James Raschke; Marina E Emborg
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

7.  An HSV-1 vector expressing tyrosine hydroxylase causes production and release of L-dopa from cultured rat striatal cells.

Authors:  A I Geller; M J During; Y J Oh; A Freese; K O'Malley
Journal:  J Neurochem       Date:  1995-02       Impact factor: 5.372

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.